european network for the study of adrenal tumors

Executive committee

Chair of the Executive Committee

Martin Fassnacht, MD
 Head of the Division of Endocrinology and Diabetes
 Department of Internal Medicine I
 University Hospital Würzburg
 Oberdürrbacherstr. 6
 Würzburg, Germany

Martin Fassnacht is Professor of Internal Medicine and Endocrinology at the University of Würzburg. He is head of the Division of Endocrinology and Diabetes at the University Hospital Würzburg. The main interest of his clinical and translational research group is endocrine tumors with a special focus on adrenal tumors. He run(s) several clinical trials for patients with adrenocortical carcinoma and malignant pheochromocytoma and his translational group is adrenocortical tumorigenesis and drug targets for adrenocortical carcinoma.

Period in office: 2016-2021


Pr Guillaume Assié

Endocrine department, Cochin hospital, APHP, Paris

Institut Cochin, Inserm CNRS, Université de Paris

Paris, France

Guillaume Assié is professor of Endocrinology in Université de Paris, working in the Endocrine department of Cochin hospital in Paris.  He is specialized in general Endocrinology, mainly Cushing syndromes, adrenal tumors, and pituitary diseases.

His research activity is mainly focused on bioinformatics, mainly working on the genomic alterations of endocrine tumors, including adrenal tumors.

Period in office: 2019-2022


Henri Timmers, MD, PhD
 Division of Endocrinology
 Department of Internal Medicine
 Radboud University Medical Centre
 Geert Grooteplein Zuid 8
 Radboud, The Netherlands

Henri Timmers (1971), M.D./Ph.D., is clinical endocrinologist and assistant professor at the Department of Medicine, section of Endocrinology, Radboud University Medical Centre, in Nijmegen, the Netherlands. He is head of the Radboud Adrenal Center and member of the steering committees of ENS@T and the international  Pheochromocytoma and Paraganglioma Research Support Organization (PRESSOR). His principle clinical and scientific focus is on adrenal diseases, especially pheochromocytoma and paraganglioma.

Period in office: 2019-2022

Other members of the Executive Committee